First commercially available fully validated ELISA to reliably measure Vanin-1 in human urine samples from Biomedica.
Vanin-1 is a glycoprotein that is selectively expressed in renal tubular cells.
Urinary Vanin-1
- has as superior predictive value for drug induced AKI than KIM-1 or NGAL
- is a novel biomarker to detect and monitor the clinical course of obstructive nephropathy
Biomedica offers the FIRST fully validated VANIN-1 (urine) ELISA for reliable results
Try our VANIN-1 (urine) ELISA and contact us for your evaluation discount.
Related Literature & Findings:
Urinary Vanin-1 As a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury. Hosohata K et al., J Pharmoc Exp Therapeut, 2012; 656–62.
A Novel Biomarker for Acute Kidney Injury, Vanin-1, for Obstructive Nephropathy: A Prospective Cohort Pilot Study. Washino S. et al., Int J Mol Sci, 2019; 20, 4.
Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease. Unterschemmann K, Ehrmann A, Herzig I, Andreevski AL, Lustig K, Schmeck C, Eitner F, Grundmann M. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F61-F73. doi: 10.1152/ajprenal.00373.2020. Epub 2020 Nov 16. PMID: 33196323.
Abstract
Oxidative stress is a key concept in basic, translational, and clinical research to understand the pathophysiology of various disorders, including cardiovascular and renal diseases. Although attempts to directly reduce oxidative stress with redox-active substances have until now largely failed to prove clinical benefit, indirect approaches to combat oxidative stress enzymatically have gained further attention as potential therapeutic strategies. The pantetheinase Vanin-1 is expressed on kidney proximal tubular cells, and its reaction product cysteamine is described to negatively affect redox homeostasis by inhibiting the replenishment of cellular antioxidative glutathione stores. Vanin-1-deficient mice were shown to be protected against oxidative stress damage. The aim of this study was to elucidate whether pharmacological inhibition of Vanin-1 protects mice from oxidative stress-related acute or chronic kidney injury as well. By studying renal ischemia-reperfusion injury in Col4α3-/- (Alport syndrome) mice and in vitro hypoxia-reoxygenation in human proximal tubular cells we found that treatment with a selective and potent Vanin-1 inhibitor resulted in ample inhibition of enzymatic activity in vitro and in vivo. However, surrogate parameters of metabolic and redox homeostasis were only partially and insufficiently affected. Consequently, apoptosis and reactive oxygen species level in tubular cells as well as overall kidney function and fibrotic processes were not improved by Vanin-1 inhibition. We thus conclude that Vanin-1 functionality in the context of cardiovascular diseases needs further investigation and the biological relevance of pharmacological Vanin-1 inhibition for the treatment of kidney diseases remains to be proven.
BI-VAN1U – human VANIN-1 ELISA Assay Highlights:
√ Optimized for human urine samples
√ Highly SPECIFIC and DEFINED characterized antibodies
√ RELIABLE rigorously validated according to FDA/ICH/EMEA guidelines
√ QUICK one-step ELISA
Related products:
Nephrology: FGF23, Endostatin, Anti C4d
Cardiology: NT-proBNP, Endothelins, proANP, NT-proCNP
Meet us at the ASBMR in Orlando at
- The Biomedica booth # 516
- Our Posters: #SUN-103, #SUN-271, #MON-252 and #MON-331
- The Bone Turnover Markers Working Group
Room# W307B, Sept 20 at 7:30pm - Diurnal Changes in Serum Levels of Bone-Related Circulating MicroRNAs.
Oral presentation #1140, room# W314, Monday, Sept 23 from 2:15pm-2:30pm
If you cannot make it to the ASBMR contact us for your special quote.
Biomedica is proud to announce the launch of its CE-marked FGF23 (intact) human ELISA, cat# BI-20700
Features and Benefits
-
RELIABLE & FULLY VALIDATED for plasma samples – according to ICH Q2
-
SERUM, URINE and CC SUPERNATANT are compatible with this ELISA
-
FAST ONE-STEP ELISA – only 3.5 h total incubation time
-
PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
-
CHARACTERIZED MONOCLONAL RECOMBINANT ANTIBODIES – high specificity guaranteed
The new intact FGF23 ELISA was mentioned in the most recent Biocompare newsletter as a featured product. Check out the drug discovery and development newsletter to learn more.
FGF23 (intact) human ELISA
Features and Benefits
• RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2
• SERUM, URINE and CC SUPERNATANT are compatible with this ELISA
• FAST ONE-STEP ELISA – only 3.5 h total incubation time
• PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
• CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
• GOOD CORRELATION with existing ELISA methods
Why FGF23 ELISA from Biomedica?
√ Proprietary products – developed and manufactured in our European facilities
√ Excellent stability in all matrices after sample collection
√ CE registration in progress
Please click below for:
– Assay Validation Data
– Instruction For Use
– Biomedica FGF23 Info Leaflet
– Product Website
Related Product:
FGF23 (C-terminal) ELISA
Meet Biomedica Immunoassays at poster P95 “Detection of intact FGF23 using a novel well-characterized ELISA” to learn more about new FGF23 (intact) human ELISA and to discuss your research projects!
Useful links:
|
||
|
||
Göbel A. et al., J Bone Oncology, 2019; 16: 100237. Full publication.
SEMAPHORIN 4D is a soluble and membrane-bound protein
that plays important roles in physiologic processes such as vascular growth, tumor progression, and immune cell regulation.
Related literature:
The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.
Lontos K et al., Front Endocrinol, 2018; 9:322. Full publication.
A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphoring 4D in plasma.
Laber A et al., Anal Biochem, 2019; 574:15-22. Full publication.
Did you know?
Soluble Semaphorin 4D can easily be quantified with the Biomedica SEMA4D ELISA
√ HIGHLY SPECIFIC – antibodies bind with high affinities to conformational epitopes in the sema domain
√ ACCURATE – successful validation according to FDA guidelines
√ RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data
√ LOW SAMPLE VOLUME – only 10 µl / well required
√ Plasma is the suitable matrix for reproducible quantification of sSEMA4D
May 11 – 14, 2019
Meet Biomedica Immunoassays at the ECTS Congress in Budapest – booth # 12 – to learn more about our soon to be launched new assay and to discuss your research projects!
In addition to having a booth, we will present the following posters:
-
Development and characterization of an extraction-free human CGRP sandwich ELISA
-
Novel ELISA for the detection of intact FGF23
Useful links:
Scientific Program
ECTS Homepage
May 9 – 11, 2019
Meet Biomedica Immunoassays at the Osteoporoseforum in St. Wolfgang to learn more about our soon to be launched new assay and to discuss your research projects!
- intact FGF23 ELISA
- C-terminal FGF23 ELISA
- bioactive Slcerostin ELISA
Useful links:
C-type natriuretic peptide (CNP), a small peptide hormone, plays a crucial role in linear growth. The growth plate is a major contributor to circulating CNP products in the immature skeleton. Its bio-inactive aminoterminal propeptide (NTproCNP) is easily measurable in plasma, and levels reflect the rate of CNP biosynthesis.
Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth.
Espiner E et al.,Horm Res Paediatr,2019;7;90(6):345-357.
Did you know?
NT-proCNP can easily be quantified with the Biomedica 2nd generation NT-proCNP ELISA (cat.no. BI-20812)
√ HIGH SENSITIVITY – 0.7 pmol/l (= 3.49 pg/ml)
√ EASY – direct measurement – no concentration step
√ LOW SAMPLE VOLUME – only 20 µl / well required
√ ACCURATE – successful validation according to FDA guidelines
√ RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data
√ High cross-reactivity with rat NT-proCNP
Literature:
- Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature.
Olney RC et al.,Clin Endocrinol,2016;85(4):561-8. - Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia.
Kubota T et al.,Clin Endocrinol,2016;84(6):845-50. - Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death.
Fujii T et al.,PloS One,2018;13(3):e0194812.
WORLD CONGRESS ON OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES
April 4 – 7, 2019
Meet Biomedica Immunoassays at poster P676 “Novel ELISA Allows Accurate Quantification of Intact Fibroblast Growth Factor 23 (FGF23) in Serum and Plasma” to learn more about our soon to be launched new assay and to discuss your research projects!
Useful links:
Together with our partner Immundiagnostik from Bensheim, Germany, we presented Biomedica Immunoassays at the Osteologie congress in Frankfurt.
We proudly presented our soon to be launched ELISA for the quantitative measurement of intact FGF23 in a talk and generated a lot of interest in the test. The poster introducing our new bioactive Sclerostin ELISA, a test that specifically detects Sclerostin at its receptor binding site, was visited by many congress participants and was discussed a lot. Furthermore, a poster introducing our soluble Semaphorin 4D ELISA, a factor promoting skeletal metastasis, was presented the field of osteo-oncology.
We greatly enjoyed this interesting congress and look forward to next year’s Osteologie congress taking place in Salzburg, Austria!